Abstract 13652: The Anti-Hypertensive Effects of LCZ696 in Patients With Hypertension: A Meta-Analysis of Randomized Controlled Trials
Circulation（2019）
摘要
Introduction: Sacubitril/vasartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor approved for the treatment of heart failure with reduced ejection fraction. To determine the...
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要